"Jordan Pharmaceuticals & Healthcare Report Q2 2014" is now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Fri Mar 14 2014

Jordan is a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region. However, despite a number of positive factors, we highlight current cutbacks in government spending, which have directly impacted the pharmaceutical market (medicine price cuts of 10-74% in 2013), as a key concern to drugmakers. We warn that additional government measures could include a slowdown or reduction in medicines import growth, which, given the country's reliance on high-value medicines, will negatively impact multinationals that export to the country.

Headline Expenditure Projections

* Pharmaceuticals: JOD641mn (US$903mn) in 2013 to JOD675mn (US$951mn) in 2014; +5.4% in local currency terms and +5.3% in US dollar terms. Forecast revised downwards due to modifications to historical numbers, macroeconomic factors and anecdotal evidence supporting medicine price cuts.
* Healthcare: JOD2.10bn (US$2.96bn) in 2013 to JOD2.30bn (US$3.24bn) in 2014; +9.5% in local currency terms and +9.5% in US dollar terms. Forecasts revised downwards due to macroeconomic factors.

Full Report Details at
- http://www.fastmr.com/prod/777781_jordan_pharmaceuticals_healthcare_report_q2_2014.aspx?afid=303

Risk/Reward Rating: Our Risk/Reward assessment matrix ranks Jordan in 10th position, out of 30 markets surveyed in the Middle East and Africa (MEA) region in Q214 with a score of 48.6 out of 100. However, generally speaking, although Jordan offers a relatively favourable investment environment from the point of view of risks, its small population size (of about 7mn) and the possibility of political unrest will continue to pose constraints in terms of potential pharmaceutical market growth.

Key Trends And Developments


Hikma Pharmaceuticals announced it had signed a long-term commercial supply contract with Unilife Corporation ('Unilife') for the use of Unifill prefilled syringes with a range of generic injectable drugs. Hikma will pay a total of US$40mn in various payments throughout 2014 and 2015 for the exclusive global rights to use Unilife's Unifill products with a selection of Hikma's generic injectable products. Hikma has selected an initial list of around 20 of its generic injectable products to be used with Unifill products. Unilife will commence product sales to Hikma in early 2014.

The Korea International Cooperation Agency's (KOICA) Jordanian unit is set to launch several projects in the country in 2014 to support its development, according to Han Young-tae, KOICA's chief representative in Jordan. KOICA will provide support in a number of fields, such as education, energy, governance, culture and health in Jordan, Han added. The Korean agency will launch four new comprehensive healthcare centres across the country in 2014 and a special school for deaf students in Marka, which will support 400 students.


About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Sweden Pharmaceuticals & Healthcare Report Q2 2014
- Kenya Pharmaceuticals & Healthcare Report Q2 2014
- Croatia Pharmaceuticals & Healthcare Report Q2 2014
- Mexico Pharmaceuticals & Healthcare Report Q2 2014
- Thailand Pharmaceuticals & Healthcare Report Q2 2014
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »